Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.6K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

2.4K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
2.4K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Peroxiredoxin 3 Regulates Breast Cancer Progression Via Erk-mediated Mmp-1 Expression.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Peroxiredoxin 3 Regulates Breast Cancer Progression Via Erk-mediated Mmp-1 Expression.

Related Experiment Video

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Peroxiredoxin 3 regulates breast cancer progression via ERK-mediated MMP-1 expression.

Pei-Jou Chua1, Suet-Hui Ow1, Cheng-Teng Ng1

  • 1Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Queenstown, 117594, Singapore.

Cancer Cell International
|February 6, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Peroxiredoxin 3 (PRDX3) promotes breast cancer spread by activating Matrix Metalloproteinase-1 (MMP-1) through ERK signaling. Inhibiting ERK may block triple-negative breast cancer metastasis.

Keywords:
Breast carcinomaMMP-1, ERK signalingPeroxiredoxin

More Related Videos

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence
06:52

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

3.1K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.3K

Related Experiment Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K
Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence
06:52

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence

Published on: November 5, 2021

3.1K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Peroxiredoxin 3 (PRDX3) is a mitochondrial enzyme involved in oxidative stress management.
  • PRDX3 upregulation is observed during cancer development and progression.
  • Its specific role in breast cancer metastasis, particularly triple-negative breast cancer, requires further elucidation.

Purpose of the Study:

  • To investigate the role of PRDX3 in breast cancer progression and metastasis.
  • To identify the molecular mechanisms by which PRDX3 influences cancer cell invasion and migration.
  • To explore the relationship between PRDX3, Matrix Metalloproteinase-1 (MMP-1), and ERK signaling in breast cancer.

Main Methods:

  • Gene silencing using shRNA to reduce PRDX3 levels in triple-negative breast cancer cell lines.
  • Overexpression of PRDX3 to assess its impact on cell invasion and migration.
  • Immunohistochemical staining of breast cancer tissues to correlate PRDX3 and MMP-1 expression.
  • Pathway reporter arrays and luciferase assays to analyze signaling pathway activation.

    • Main Results:

    • PRDX3 gene silencing inhibited cell migration and invasion in triple-negative breast cancer cells.
    • PRDX3 overexpression promoted cancer cell invasion and migration, correlating with MMP-1 upregulation.
    • A positive correlation between PRDX3 and MMP-1 expression was found in breast cancer tissues.
    • ERK signaling pathway activation was identified as the mechanism for PRDX3-mediated MMP-1 transcriptional activation.

    Conclusions:

    • PRDX3 promotes breast cancer cell migration and invasion, key steps in metastasis.
    • PRDX3 facilitates cancer spread by upregulating MMP-1 expression via ERK signaling activation.
    • Targeting ERK signaling presents a potential therapeutic strategy to inhibit metastasis in triple-negative breast cancer.